StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Stoke Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Stoke Therapeutics's pe ratio was 45.3× on Jan 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 202645.3×−2.1
2025Dec 31, 202547.4×–

More Stoke Therapeutics figures

See a number that looks wrong?